CABA Cabaletta Bio Inc: רווח נקי למניה ב-12 החודשים האחרונים

The asset value tracked on the chart in the context of CAR-T platform scaling and asset protection is 43.20. Cabaletta Bio, Inc. (CABA) relies on the success of CABA-201 trials against systemic pathologies, which creates opportunities for an acquisition by industry behemoths. However, sanctions and political fragmentation hinder the movement of biomaterials and the conduct of global medical research, limiting patient access to therapy.

This metric reflects the year-over-year growth rate of earnings per share over the last 12 months. By analyzing the 12-month YoY EPS trend, an investor can distinguish actual operational efficiency from temporary accounting adjustments. This process helps identify hidden margin compression masked by Non-GAAP reporting. For Cabaletta Bio, Inc. (CABA), such transparency is critical when scaling trials through external vendors.